|
gptkbp:instance_of
|
gptkb:pharmaceuticals
|
|
gptkbp:administered_by
|
oral tablet
|
|
gptkbp:affects_hormone_levels
|
estrogen
|
|
gptkbp:approves
|
gptkb:2001
gptkb:FDA
|
|
gptkbp:available_in
|
many countries
|
|
gptkbp:can_be_combined_with
|
other cancer therapies
|
|
gptkbp:can_be_used_after
|
gptkb:surgery
radiation therapy
chemotherapy
|
|
gptkbp:can_cause
|
osteoporosis
|
|
gptkbp:contraindication
|
pregnancy
severe liver disease
|
|
gptkbp:developed_by
|
gptkb:Astra_Zeneca
|
|
gptkbp:dosage_form
|
2.5 mg tablet
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
letrozole
|
|
gptkbp:increases_survival_rate
|
postmenopausal women with hormone receptor-positive breast cancer
|
|
gptkbp:interacts_with
|
gptkb:tamoxifen
estrogen
|
|
gptkbp:investigates
|
gptkb:disease
gptkb:rhabdomyosarcoma
gptkb:gastrointestinal_stromal_tumors
gptkb:sarcophagus
gptkb:Oncology
gptkb:Chondrichthyes
gptkb:Kaposi's_sarcoma
gptkb:pancreatic_cancer
gptkb:neurofibromatosis
gptkb:Ewing's_sarcoma
gptkb:cervical_cancer
gptkb:Wilms_tumor
gptkb:neuroblastoma
gptkb:choriocarcinoma
gptkb:angiosarcoma
gptkb:clear_cell_sarcoma
gptkb:dedifferentiated_liposarcoma
gptkb:dermatofibrosarcoma
gptkb:desmoplastic_small_round_cell_tumor
gptkb:hemangiopericytoma
gptkb:inflammatory_myofibroblastic_tumor
gptkb:malignant_melanoma
gptkb:malignant_peripheral_nerve_sheath_tumor
gptkb:malignant_schwannoma
gptkb:myxoid_liposarcoma
gptkb:neuroendocrine_carcinoma
gptkb:pleomorphic_liposarcoma
gptkb:solitary_fibrous_tumor
gptkb:synovial_sarcoma
gptkb:thymic_cancer
ovarian cancer
endometrial cancer
esophageal cancer
osteosarcoma
bladder cancer
head and neck cancer
neuroendocrine tumors
adrenocortical carcinoma
carcinoid tumors
other cancers
gastrointestinal neuroendocrine tumors
peripheral nerve sheath tumor
|
|
gptkbp:is_a
|
gptkb:Android
hormone replacement therapy
|
|
gptkbp:is_considered
|
second-line treatment
first-line treatment
|
|
gptkbp:is_monitored_by
|
bone density
|
|
gptkbp:is_part_of
|
adjuvant therapy
neoadjuvant therapy
|
|
gptkbp:is_studied_in
|
clinical trials
|
|
gptkbp:is_used_in
|
male breast cancer treatment
|
|
gptkbp:marketed_as
|
gptkb:Femara
|
|
gptkbp:mechanism_of_action
|
inhibits aromatase enzyme
|
|
gptkbp:prescribed_by
|
oncologists
|
|
gptkbp:reduces_recurrence_risk
|
gptkb:Oncology
|
|
gptkbp:scientific_classification
|
gptkb:fragrance
|
|
gptkbp:side_effect
|
fatigue
nausea
joint pain
hot flashes
|
|
gptkbp:suitable_for
|
pre-menopausal women
|
|
gptkbp:used_for
|
gptkb:Oncology
|
|
gptkbp:bfsParent
|
gptkb:Verzenio
|
|
gptkbp:bfsLayer
|
5
|